Compare Stocks: GALT, CADL, DRUG, and PHAR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.59 +0.1%	$9.44	$4.35 ▼ $11.36	$775.93M	-0.51	1.21 million shs	798,419 shs
DRUG Bright Minds Biosciences	$79.33 -1.8%	$70.32	$34.19 ▼ $123.75	$772.06M	-5.27	231,029 shs	156,403 shs
GALT Galectin Therapeutics	$3.45 +7.1%	$3.52	$2.03 ▼ $7.13	$227.21M	0.41	550,649 shs	322,012 shs
PHAR Pharming Group	$10.85	$12.74	$9.62 ▼ $21.34	$775.02M	-0.01	10,554 shs	6,391 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	+5.79%	+7.08%	+26.83%	+77.68%
DRUG Bright Minds Biosciences	0.00%	+8.29%	+1.45%	-7.22%	+122.90%
GALT Galectin Therapeutics	0.00%	+16.16%	-21.05%	+64.29%	-8.49%
PHAR Pharming Group	0.00%	+7.64%	-22.72%	-16.41%	-11.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$10.59 +0.1%	$9.44	$4.35 ▼ $11.36	$775.93M	-0.51	1.21 million shs	798,419 shs
DRUG Bright Minds Biosciences	$79.33 -1.8%	$70.32	$34.19 ▼ $123.75	$772.06M	-5.27	231,029 shs	156,403 shs
GALT Galectin Therapeutics	$3.45 +7.1%	$3.52	$2.03 ▼ $7.13	$227.21M	0.41	550,649 shs	322,012 shs
PHAR Pharming Group	$10.85	$12.74	$9.62 ▼ $21.34	$775.02M	-0.01	10,554 shs	6,391 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	+5.79%	+7.08%	+26.83%	+77.68%
DRUG Bright Minds Biosciences	0.00%	+8.29%	+1.45%	-7.22%	+122.90%
GALT Galectin Therapeutics	0.00%	+16.16%	-21.05%	+64.29%	-8.49%
PHAR Pharming Group	0.00%	+7.64%	-22.72%	-16.41%	-11.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.60	Moderate Buy	$18.57	75.37% Upside
DRUG Bright Minds Biosciences	3.14	Buy	$143.83	81.31% Upside
GALT Galectin Therapeutics	1.67	Reduce	$11.00	218.84% Upside
PHAR Pharming Group	2.20	Hold	$38.67	256.37% Upside

Current Analyst Ratings Breakdown

Latest GALT, CADL, DRUG, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
7/31/2026	PHAR Pharming Group	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/30/2026	PHAR Pharming Group	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/29/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
7/21/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	CADL Candel Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	CADL Candel Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$22.00
7/13/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/23/2026	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
6/18/2026	GALT Galectin Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/1/2026	DRUG Bright Minds Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$145.00

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
PHAR Pharming Group	$366.48M	2.10	$0.20 per share	54.60	$3.82 per share	2.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$38.18M	-$0.98	N/A	N/A	N/A	N/A	-60.42%	-41.33%	8/13/2026 (Estimated)
DRUG Bright Minds Biosciences	-$8.74M	-$2.44	N/A	N/A	N/A	N/A	-20.58%	-20.25%	8/13/2026 (Estimated)
GALT Galectin Therapeutics	-$30.84M	-$0.41	N/A	N/A	N/A	N/A	N/A	-164.69%	8/13/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	90.42	36.17	N/A	2.51%	3.40%	1.90%	N/A

Latest GALT, CADL, DRUG, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.22	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2831	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	N/A	N/A	N/A	N/A	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	$90.20 million
5/20/2026	Q2 2026	DRUG Bright Minds Biosciences	-$0.8633	-$0.80	+$0.0633	-$0.80	N/A	N/A
5/15/2026	Q1 2026	GALT Galectin Therapeutics	-$0.06	-$0.08	-$0.02	-$0.08	N/A	N/A
5/14/2026	Q1 2026	CADL Candel Therapeutics	-$0.2958	-$0.14	+$0.1558	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.34	28.05	28.05
DRUG Bright Minds Biosciences	N/A	81.47	81.47
GALT Galectin Therapeutics	N/A	2.15	2.15
PHAR Pharming Group	0.34	3.01	2.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
DRUG Bright Minds Biosciences	40.52%
GALT Galectin Therapeutics	11.68%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
DRUG Bright Minds Biosciences	42.66%
GALT Galectin Therapeutics	52.60%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	73.27 million	62.79 million	Optionable
DRUG Bright Minds Biosciences	N/A	9.73 million	5.58 million	Not Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
PHAR Pharming Group	280	70.78 million	69.31 million	Not Optionable

GALT, CADL, DRUG, and PHAR Headlines

Recent News About These Companies

Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky

August 7 at 10:05 AM | prnewswire.com

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 5, 2026 | tmcnet.com

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.

August 5, 2026 | businesswire.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Time to Buy?

August 5, 2026 | marketbeat.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)

August 5, 2026 | globenewswire.com

Pharming Group (NASDAQ:PHAR) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

August 5, 2026 | americanbankingnews.com

PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)

August 4, 2026 | tmcnet.com

Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | finance.yahoo.com

Canaccord Genuity Group Forecasts Strong Price Appreciation for Pharming Group (NASDAQ:PHAR) Stock

August 3, 2026 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Pharming Group

August 3, 2026 | americanbankingnews.com

Q3 EPS Estimates for Pharming Group Lowered by HC Wainwright

August 3, 2026 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down After Earnings Miss

August 2, 2026 | americanbankingnews.com

Pharming Group (NASDAQ:PHAR) Hits New 12-Month Low Following Weak Earnings

August 1, 2026 | americanbankingnews.com

Pharming Group (NASDAQ:PHAR) Posts Earnings Results, Misses Expectations By $0.04 EPS

July 31, 2026 | marketbeat.com

Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)

July 31, 2026 | prnewswire.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down Following Weak Earnings

July 31, 2026 | marketbeat.com

Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader ...

July 30, 2026 | markets.businessinsider.com

Pharming Group下调2026年营收指引3000万美元，销售疲软拖累业绩

July 30, 2026 | cn.investing.com

Pharming Group mist Q2 2026 omzetverwachting, aandeel daalt 22%

July 30, 2026 | nl.investing.com

Pharming Group (NASDAQ:PHAR) Sets New 12-Month Low Following Weak Earnings

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GALT, CADL, DRUG, and PHAR Company Descriptions

Candel Therapeutics NASDAQ:CADL

$10.59 +0.01 (+0.09%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$10.58 -0.01 (-0.11%)

As of 08/7/2026 07:56 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Bright Minds Biosciences NASDAQ:DRUG

$79.33 -1.47 (-1.82%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$79.00 -0.33 (-0.41%)

As of 08/7/2026 07:34 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Galectin Therapeutics NASDAQ:GALT

$3.45 +0.23 (+7.14%)

As of 08/7/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Pharming Group NASDAQ:PHAR

$10.85 0.00 (0.00%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$10.85 0.00 (0.00%)

As of 08/7/2026 07:34 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GALT, CADL, DRUG, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GALT, CADL, DRUG, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GALT, CADL, DRUG, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GALT, CADL, DRUG, and PHAR Company Descriptions

Candel Therapeutics NASDAQ:CADL

Bright Minds Biosciences NASDAQ:DRUG

Galectin Therapeutics NASDAQ:GALT

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GALT, CADL, DRUG, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GALT, CADL, DRUG, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GALT, CADL, DRUG, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GALT, CADL, DRUG, and PHAR Company Descriptions

Candel Therapeutics NASDAQ:CADL

Bright Minds Biosciences NASDAQ:DRUG

Galectin Therapeutics NASDAQ:GALT

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools